Cite
van Koningsbruggen-Rietschel S, Davies JC, Pressler T, et al. Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study. ERJ Open Res. 2020;6(4)doi: 10.1183/23120541.00132-2020.
van Koningsbruggen-Rietschel, S., Davies, J. C., Pressler, T., Fischer, R., MacGregor, G., Donaldson, S. H., Smerud, K., Meland, N., Mortensen, J., Fosbøl, M. �. �., Downey, D. G., Myrset, A. H., Flaten, H., & Rye, P. D. (2020). Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study. ERJ open research, 6(4), . https://doi.org/10.1183/23120541.00132-2020
van Koningsbruggen-Rietschel, Silke, et al. "Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study." ERJ open research vol. 6,4 (2020). doi: https://doi.org/10.1183/23120541.00132-2020
van Koningsbruggen-Rietschel S, Davies JC, Pressler T, Fischer R, MacGregor G, Donaldson SH, Smerud K, Meland N, Mortensen J, Fosbøl MØ, Downey DG, Myrset AH, Flaten H, Rye PD. Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study. ERJ Open Res. 2020 Oct 19;6(4). doi: 10.1183/23120541.00132-2020. eCollection 2020 Oct. PMID: 33123558; PMCID: PMC7569163.
Copy
Download .nbib